Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Mallinckrodt
Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,669,009

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 9,669,009 protect, and when does it expire?

Patent 9,669,009 protects SPRITAM and is included in one NDA.

This patent has seventeen patent family members in nine countries.

Summary for Patent: 9,669,009
Title:Rapid disperse dosage form containing levetiracetam
Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
Inventor(s): Jacob; Jules (Yardley, PA), Coyle; Norman (Fort Washington, PA), West; Thomas G. (Lawrenceville, NJ), Monkhouse; Donald C. (Radnor, PA), Surprenant; Henry L. (Phoenixville, PA), Jain; Nemichand B. (Princeton Junction, NJ)
Assignee: Aprecia Pharmaceuticals Company (Langhorne, PA)
Application Number:15/095,785
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,669,009

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS   Start Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM   Start Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS   Start Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 RX Yes No   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS   Start Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 RX Yes No   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS   Start Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 RX Yes No   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM   Start Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-002 Jul 31, 2015 RX Yes No   Start Trial   Start Trial METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,669,009

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014228990   Start Trial
Australia 2017202752   Start Trial
Canada 2906029   Start Trial
China 105188849   Start Trial
China 109908355   Start Trial
European Patent Office 2968994   Start Trial
European Patent Office 3431141   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Colorcon
AstraZeneca
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.